Seralutinib is a small molecule commercialized by Gossamer Bio, with a leading Phase II program in Pulmonary Arterial Hypertension. According to Globaldata, it is involved in 6 clinical trials, of which 3 were completed, 1 is ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Seralutinib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Seralutinib is expected to reach an annual total of $218 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Seralutinib is under development for the treatment of pulmonary arterial hypertension (PAH). It acts by targeting CSF1R, c-KIT, PDGF subtype a and PDGFB. The drug candidate is administered as an inhalation in the form of powder. It is administered orally as a capsule. It is developed based on PDGFR kinase technology.
Gossamer Bio Overview
Gossamer Bio is a biopharmaceutical company that involves discovering, developing, and commercializing medicines for the disease areas of immunology, inflammation, and oncology. The company’s product portfolio includes GB002, for pulmonary arterial hypertension; GB5121 for adult patients with relapsed/refractory CNS lymphoma, and GB7208 for multiple sclerosis. The company is funded by Arch Venture Partners LP, Omega Fund Management LLC, and Hillhouse Capital Group. Gossamer Bio is headquartered in San Diego, California, the US.
The operating loss of the company was US$216.1 million in FY2021, compared to an operating loss of US$234 million in FY2020. The net loss of the company was US$234 million in FY2021, compared to a net loss of US$243.4 million in FY2020.
For a complete picture of Seralutinib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.